Version history

{
  "session_id": "sess-hyp-1b87d283fc0c",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: TREM2 Agonism for Alzheimer's Disease\n\n## Executive Summary\n\nThe TREM2 hypothesis remains one of the most genetically validated targets in Alzheimer's disease drug development, but faces significant translational hurdles that temper enthusiasm despite the 0.82 confidence score. The genetic architecture (R47H as strong loss-of-function risk variant) provides compelling justification for agonist approaches, yet pharmacology complexity and clinical translation gaps create meaningful uncertainty.\n\n---\n\n## Target Druggability Assessment\n\n### Classification\n**TREM2 is a \"druggable but challenging\" target** — a cell-surface receptor in the immunoglobulin superfamily with limited extracellular surface amenable to small-molecule binding.\n\n**Why it is druggable:**\n- Agonistic monoclonal antibodies (mAbs) represent the primary modality — consistent with the current development landscape (AL002c and analogous programs)\n- Receptor density on microglia surface (~10³–10⁴ copies/cell) is sufficient for antibody engagement\n- SYK/PLCγ2 cascade downstream is well-characterized and provides pharmacodynamic biomarkers (p-SYK, p-PLCγ2)\n\n**Why it's challenging:**\n- Ligand-binding Ig domain (where R47H resides) has flat, lipid-interaction surfaces poorly suited for small-molecule agonism\n- Structural biology of TREM2 activation remains incomplete — the conformational changes required for SYK recruitment are not definitively mapped\n- Cell-type selectivity (preferentially microglia vs. infiltrating macrophages) is not assured with systemically administered antibodies due to blood-brain barrier penetration variability\n\n### Confidence in Mechanism: **Moderate-High**\n\n| Evidence Type | Status |\n|--------------|--------|\n| Human genetics (R47H, other LOF variants) | Strong |\n| Mouse model knockout phenotypes | Moderate (paradoxical depending on model) |\n| Antibody-induced pathway activation | Demonstrated in vitro |\n| Downstream functional readouts (phagocytosis, plaque compaction) | Shown in mouse models |\n| Human translational validation | Limited |\n\n---\n\n## Tool Compounds and Development Landscape\n\n### Clinical/Preclinical Assets\n\n| Compound | Developer | Stage | Key Characteristics |\n|----------|-----------|-------|---------------------|\n| **AL002c** | Alector | Phase 2 (Pivot) | Humanized IgG1, full agonism, entered 2023 |\n| **AL002** | Alector | Phase 1 complete | Earlier formulation, safety signal monitored |\n| **DNL311** | Denali | Phase 1",
  "tokens_used": "621",
  "persona_id": "persona-domain_expert"
}